Merck's Personalized mRNA Cancer Vaccine Shows Durable Melanoma Results

What happened

Merck and Moderna unveiled long-term results from the KEYNOTE-942 phase 2b clinical trial at the American Society of Clinical Oncology (ASCO) Annual Meeting. The study evaluated 157 patients with high-risk stage 3 and stage 4 melanoma whose tumors had been surgically removed. Participants received either a combination of intismeran autogene (a personalized mRNA cancer vaccine) plus KEYTRUDA (pembrolizumab) or KEYTRUDA alone. After nearly five years of follow-up, the combination therapy reduced the risk of melanoma recurrence or death by 49% compared to the immunotherapy drug alone. The researchers reported that benefits remained "sustained and durable over time." Intismeran autogene is designed using mutations identified in each patient's own tumor to train the immune system to recognize and attack cancer cells. The treatment was well-tolerated, with the most common side effects being fatigue, injection-site pain, chills, fever, and headache. No new long-term safety concerns or severe vaccine-related adverse events were observed. The combination therapy has now advanced to a phase 3 trial, the final stage typically required before regulatory approval.

Why it matters

This data represents a meaningful milestone for Merck's oncology pipeline and its collaboration with Moderna in personalized cancer immunotherapy. Many patients with advanced melanoma face significant risk of recurrence even after surgery, and the durability of the 49% risk reduction over five years suggests the combination therapy could address a substantial unmet medical need. KEYTRUDA is already a key revenue driver for Merck, and adding a personalized mRNA vaccine could differentiate its melanoma franchise and expand its competitive position in immuno-oncology. The favorable long-term safety profile and absence of severe vaccine-related adverse events support the therapy's commercial viability if approved. The advancement to phase 3 trials brings the treatment closer to potential regulatory approval and market entry.

Bigger picture

This development reflects the broader promise of mRNA technology beyond infectious disease vaccines, an area Moderna has pioneered and Merck is investing in through strategic partnerships. Personalized cancer vaccines represent a frontier in precision oncology, where treatments are tailored to individual tumor profiles. The encouraging five-year data strengthens the case for mRNA-based therapeutics in oncology and could accelerate investment and development across the pharmaceutical sector. Merck also noted upcoming late-stage INTerpath trial results with Moderna in several hard-to-treat cancers, signaling a pipeline of additional mRNA-based therapies. Success in melanoma could pave the way for broader applications in other tumor types, potentially reshaping treatment paradigms in oncology.

What to watch

Investors should monitor the timing and results of the phase 3 trial, as positive data would be critical for regulatory submissions and potential approval. Any updates on the INTerpath late-stage program in other cancer types will provide insight into the scalability and versatility of the mRNA platform. Watch for regulatory filings with the FDA or other global health authorities, which could signal commercialization timelines. Competitive developments in personalized cancer vaccines and immuno-oncology combinations will also be important, as other pharmaceutical companies are exploring similar approaches. Finally, any commentary from Merck on the commercial strategy, pricing, and market potential for intismeran autogene will help frame the long-term financial opportunity.